sabcs 2017: adjuvant trastuzumab did not improve outcomes for patients with her2-low breast cancer
Published 6 years ago • 274 plays • Length 12:04Download video MP4
Download video MP3
Similar videos
-
7:40
adjuvant trastuzumab did not improve outcomes for patients with her2-low breast cancer
-
13:56
sabcs 2017: immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
5:29
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
14:24
adjuvant capecitabine did not significantly improve outcomes for early-stage tnbc
-
4:01
trastuzumab deruxtecan: a promising agent for treating her2-low breast cancer?
-
7:31
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
4:01
her2low invasive breast cancer: trastuzumab offers no improvement for invasive disease free survival
-
14:37
sabcs 2017: 2 years of extended anastrozole therapy proved as effective as 5 years
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
6:17
sara tolaney, sabcs 2022: adjuvant paclitaxel and trastuzumab for node-negative her2 breast cancer
-
21:58
session 10: adjuvant treatment in patients with her2 positive breast cancer: risk stratification...
-
24:19
sabcs 2017 roundtable with dr. hope s. rugo and dr. william j. gradishar
-
10:05
piii trial supports current standard 12-month adjuvant trastuzumab for her2-positive breast cancer
-
0:30
the role of serds in the treatment landscape of patients with er /her2- breast cancer
-
17:10
sabcs 2022: trio-us b-12 talent: neoadjuvant tdx with or without anastrozole for her2-low, hr e...
-
2:59
talent: neoadjuvant t-dxd with or without anastrozole for her2-low, hr early stage breast cancer
-
6:51
adcs for her2 and her2-low breast cancer